Bosutinib
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively[1].
Product Specifications
CAS Number
380843-75-4
Product Name Alternative
SKI-606
UNSPSC
12352005
Hazard Statement
H319, H413
Target
Autophagy; Bcr-Abl; Src
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Bosutinib.html
Purity
99.96
Solubility
DMSO : ≥ 46 mg/mL
Smiles
CN1CCN(CC1)CCCOC2=C(C=C3C(NC4=CC(OC)=C(C=C4Cl)Cl)=C(C=NC3=C2)C#N)OC
Molecular Formula
C26H29Cl2N5O3
Molecular Weight
530.45
Precautions
H319, H413
References & Citations
[1]Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30 (28) :3486-92.|[2]Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66 (23) :11314-22.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741037-100 1x 100 µL
CD44 Standard (DF1485), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470734-500 1x 500 µL
TAG-72 / CA72.4 (B72.3 + CA72/733), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940819-100 1x 100 µL
Caldesmon, HMW (h-Caldesmon) (h-CALD), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 